Charles River Laboratories Intl. Inc (N:CRL)

Business Focus: Biotechnology & Medical Research

Jul 14, 2020 08:30 am ET
Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2020 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:30 a.m. ET.
Jun 02, 2020 08:00 am ET
HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio
HemaCare Corporation, a Charles River Laboratories International, Inc. (NYSE:CRL) company and global leader and trusted brand in the customization of human-derived biological products and services for biomedical research, drug discovery, and cellular therapy process development, today announced that it has expanded its portfolio of GMP-compliant
Jun 01, 2020 08:00 am ET
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, at 10:00 a.m. ET, and at the William Blair 40th Annual Growth Stock Conference on Tuesday, June 9th, at 10:00 a.m. CT (11:00 a.m. ET). Management will present an overview of Charles River’s strategic focus and business developments.
May 07, 2020 07:00 am ET
Charles River Laboratories Announces First-Quarter 2020 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2020. For the quarter, revenue was $707.1 million, an increase of 17.0% from $604.6 million in the first quarter of 2019.
Apr 16, 2020 08:30 am ET
Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call
Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.
Mar 30, 2020 08:30 am ET
Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service.
Mar 10, 2020 08:30 am ET
Charles River Laboratories To Participate In Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will participate in the Barclays Global Healthcare Conference. The Company will present on Wednesday, March 11th, at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments.
Mar 04, 2020 08:00 am ET
Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews, M.D., Ph.D., to its Board of Directors, effective February 28, 2020. Dr. Andrews is Duke University’s Dean Emerita of its School of Medicine, Vice Chancellor Emerita for Academic Affairs, and Professor of Pediatrics, Pharmacology, and Cancer Biology. She is also on the Board of Directors of Novartis AG. Dr. Andrews’s extensive experience as a physician, scientist, professor, and senior administrator at leading academic institutions and hospitals will enhance the scienti
Feb 11, 2020 07:00 am ET
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2019 and provided guidance for 2020. For the quarter, revenue was $691.1 million, an increase of 14.9% from $601.5 million in the fourth quarter of 2018.
Jan 21, 2020 04:30 pm ET
Charles River Laboratories Schedules Fourth-Quarter 2019 Earnings and 2020 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2019 financial results and provide 2020 guidance on Tuesday, February 11th, before the market opens. A conference call has been scheduled to discuss this information on Tuesday, February 11th, at 8:30 a.m. ET.
Jan 16, 2020 08:00 am ET
Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Fios Genomics, a leading provider of bioinformatics data analysis services.
Jan 13, 2020 08:30 am ET
Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates
Charles River (NYSE: CRL) today announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Together, Charles River and Takeda will launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare disease—with the ultimate goal of delivering preclinical candidates that Takeda can advance into clinical development.
Jan 13, 2020 08:00 am ET
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14th, at 9:30 a.m. PST (12:30 p.m. EST), followed by a question and answer session at 10:00 a.m. PST (1:00 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.
Jan 03, 2020 08:30 am ET
Charles River Laboratories Completes the Acquisition of HemaCare Corporation
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380 million in cash, or $25.40 per HemaCare share. HemaCare will become part of Charles River’s Research Models and Services segment.
Dec 16, 2019 07:00 am ET
Charles River Laboratories to Acquire HemaCare Corporation
Charles River Laboratories International, Inc. (NYSE: CRL) and HemaCare Corporation (OTCMKTS: HEMA) announced today a definitive agreement for Charles River to acquire HemaCare for approximately $380 million in cash.
Dec 10, 2019 08:00 am ET
Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive Discovery and Safety Services partnership with Bit Bio, a company that offers consistent and efficient reprogramming of human cells for use in research, drug discovery, and cell therapies.
Dec 09, 2019 04:30 pm ET
Distributed Bio Launches Cosmic Antibody Library, Provides Charles River Clients Exclusive Access
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the Company will provide clients exclusive access to the new Cosmic antibody library launched by Distributed Bio, Inc., a global leader in computational optimization of fully human monoclonal antibody libraries.
Dec 04, 2019 04:30 pm ET
Charles River Laboratories Updates Tumor Model Compendium
Charles River Laboratories International, Inc. (NYSE: CRL) today announced updates to its online Tumor Model Compendium. Charles River’s cancer model database provides access to a comprehensive collection of well-established tumor models for early-stage oncology research.
Nov 11, 2019 08:30 am ET
Charles River Laboratories to Present at Upcoming Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including:
Nov 06, 2019 07:00 am ET
Charles River Laboratories Announces Third-Quarter 2019 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3 million in the third quarter of 2018.
Oct 23, 2019 04:30 pm ET
Charles River Laboratories Announces Closing of Senior Notes Offering
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 4.25% senior notes due 2028 (the “notes”) in an unregistered offering.
Oct 21, 2019 04:30 pm ET
Charles River Laboratories Schedules Third-Quarter 2019 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2019 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:00 a.m. ET.
Oct 21, 2019 08:05 am ET
Charles River Laboratories Announces Offering of $500 Million of Senior Notes
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $500 million in aggregate principal amount of senior notes due 2028 (the “notes”) in an unregistered offering, subject to market conditions.
Oct 16, 2019 04:30 pm ET
Charles River Laboratories Demonstrates Industry-Leading Research at Neuroscience 2019
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 37 scientific posters, both independently and collaboratively with clients, at Neuroscience 2019, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together more than 30,000 researchers from 70 countries, will take place from October 19-23, in Chicago, Illinois.
Oct 03, 2019 08:00 am ET
Charles River Laboratories Joins Dementia Consortium, Reaffirms Commitment to Neuroscience Research
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that the Company has been selected by Alzheimer’s Research UK to join the Dementia Consortium. The Consortium is a global charity-industry partnership aimed at funding promising research from academia and helping progress projects with the scale and strength of industry supporters.
Oct 01, 2019 08:00 am ET
Charles River Laboratories Adds Virginia M. Wilson to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Virginia M. (Gina) Wilson, the recently retired Senior Executive Vice President and Chief Financial Officer of Teachers Insurance and Annuity Association of America (TIAA), to its Board of Directors. Ms. Wilson’s extensive financial management experience across multiple industries will enhance the strategic and financial advisory expertise of Charles River’s Board of Directors. As a member of the Board, she will serve on the Audit Committee and the Corporate Governance and Nominating Committee.
Sep 09, 2019 08:00 am ET
Charles River Laboratories Announces Updates to Microbial Solutions Product Portfolio
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of two new products in its Microbial Solutions portfolio: an updated EndoScan-V™ software platform for endotoxin detection and measurement; and the introduction of the Celsis® automated detection solution for rapid sterility to ensure continued product quality and contamination control for pharmaceutical manufacturing clients.
Sep 05, 2019 04:30 pm ET
Charles River Laboratories to Host 3rd Annual World Congress
Charles River Laboratories International, Inc. is proud to host the 3rd Annual World Congress: Delivering Therapies to the Clinic Faster on September 23-24, 2019 in Cambridge, Mass. This year’s World Congress will explore novel approaches to drug development that effectively reduce program timelines and accelerate delivery to the clinic.
Sep 03, 2019 04:30 pm ET
Charles River Laboratories to Present at Baird and Morgan Stanley Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Baird 2019 Global Healthcare Conference in New York on Thursday, September 5th, at 10:15 a.m. EDT, and at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 10th, at 10:00 a.m. EDT.
Jul 31, 2019 07:00 am ET
Charles River Laboratories Announces Second-Quarter 2019 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2019. For the quarter, revenue was $657.6 million, an increase of 12.3% from $585.3 million in the second quarter of 2018.
Jul 16, 2019 04:15 pm ET
Charles River Laboratories Schedules Second-Quarter 2019 Earnings Release and Conference Call
Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.
Jul 09, 2019 08:00 am ET
Charles River Laboratories to Open Flexible Vivarium Space for Clients in South San Francisco
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the planned opening of the Charles River Accelerator and Development Lab (CRADL™) in South San Francisco in early 2020. CRADL provides flexible, turnkey vivarium rental space supported by Charles River’s technical, vivarium, and veterinary support expertise in key biohubs.
Jun 03, 2019 08:30 am ET
Charles River Laboratories to Present at Jefferies and Goldman Sachs Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
May 16, 2019 08:00 am ET
Charles River Laboratories Invests in Resero Analytics™
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has invested in Resero Analytics™, a software company focused on providing solutions to the biopharmaceutical industry to harness its data.
May 07, 2019 07:00 am ET
Charles River Laboratories Announces First-Quarter 2019 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2019. For the quarter, revenue was $604.6 million, an increase of 22.4% from $494.0 million in the first quarter of 2018. Revenue growth was driven by all three business segments, particularly Discovery and Safety Assessment and Manufacturing Support.
May 03, 2019 03:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL
Pomerantz LLP is investigating claims on behalf of investors of Charles River Laboratories International, Inc. (“Charles River” or the “Company”) (NYSE: CRL).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...
May 02, 2019 10:20 pm ET
Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. (CRL) on Behalf of Stockholders and Encourages CRL Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Charles River Laboratories International, Inc. (NYSE: CRL).  Our investigation concerns whether Charles River has violated the federal securities laws and/or engaged in other...
May 01, 2019 08:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL
NEW YORK, May 1, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Charles River Laboratories International, Inc. ("Charles River" or the "Company") (NYSE: CRL).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
May 01, 2019 08:55 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Charles River Laboratories International, Inc. - CRL
NEW YORK, May 1, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Charles River Laboratories International, Inc. ("Charles River" or the "Company") (NYSE: CRL).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Apr 29, 2019 07:00 am ET
Charles River Laboratories Completes the Acquisition of Citoxlab
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to customary closing adjustments.
Apr 11, 2019 08:30 am ET
Charles River Laboratories Schedules First-Quarter 2019 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2019 financial results on Tuesday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Tuesday, May 7th, at 8:30 a.m. ET.
Apr 09, 2019 08:00 am ET
Charles River Laboratories and CHDI Foundation Extend Huntington’s Disease Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and CHDI Foundation today announced a five-year extension of their ongoing collaboration. The organizations began working together in 2005 on drug discovery and development for Huntington’s disease (HD), a genetic neurological disease that causes t
Mar 26, 2019 08:00 am ET
Charles River Laboratories Highlights Commitment to Oncology Research at 2019 AACR Annual Meeting
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeting, with 19 scientific posters and two oral presentations to highlight its enhanced oncology portfolio. The meeting is taking place from March 29-April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.
Mar 25, 2019 07:40 am ET
Report: Developing Opportunities within Bristol-Myers Squibb, AutoNation, FirstEnergy, Charles River Laboratories International, Yum! Brands, and AGNC Investment — Future Expectations, Projections Mov
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Bristol-Myers Squibb Company (NYSE:BMY), AutoNation, Inc. (NYSE:AN),...
Mar 04, 2019 08:30 am ET
Charles River Laboratories to Present at Raymond James and Barclays Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
Feb 13, 2019 07:01 am ET
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2018 and provided guidance for 2019. For the quarter, revenue was $601.5 million, an increase of 25.7% from $478.5 million in the fourth quarter of 2017.
Feb 13, 2019 07:00 am ET
Charles River Laboratories Signs Binding Offer to Acquire Citoxlab
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a binding offer to acquire Citoxlab for €448 million in cash (or approximately $510 million based on current exchange rates), subject to customary closing adjustments. The proposed transaction is expected to close in the second quarter of 2019, subject to labor consultations, regulatory requirements, and customary closing conditions. Upon completion of the labor consultations, Citoxlab’s shareholders are expected to enter into a definitive purchase agre
Jan 30, 2019 08:00 am ET
Charles River Laboratories and Toxys Enter Agreement to Offer ToxTracker® in North America
Charles River Laboratories International, Inc (NYSE: CRL) and Toxys have entered into an agreement to offer access to ToxTracker® in North America. ToxTracker is a suite of assays that allow rapid carcinogenicity toxicity hazard identification in novel and existing drugs, chemicals, and other substances.
Jan 18, 2019 07:25 am ET
Consolidated Research: 2019 Summary Expectations for Electronic Arts, Charles River Laboratories International, Cooper-Standard, Five Below, Emerge Energy Services LP, and Hornbeck Offshore Services —
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Electronic Arts Inc. (NASDAQ:EA), Charles River Laboratories...
Jan 17, 2019 08:30 am ET
Charles River Laboratories Schedules Fourth-Quarter 2018 Earnings and 2019 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2018 financial results and provide 2019 guidance on Wednesday, February 13th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 13th, at 8:30 a.m. ET.
Jan 16, 2019 08:00 am ET
Charles River Laboratories Selected for 2019 Bloomberg Gender-Equality Index
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it is pleased to have been selected as one of 230 companies for the 2019 Bloomberg Gender-Equality Index (GEI), which distinguishes companies committed to transparency in gender reporting and advancing gender diversity. For Charles River, the GEI inclusion affirms the Company’s commitment to maintaining a positive and fulfilling work environment for all employees.
Jan 11, 2019 08:00 am ET
Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery
Charles River Laboratories International, Inc. (NYSE: CRL) and Atomwise, Inc. today announced the formation of a strategic alliance that offers clients access to Atomwise’s artificial intelligence (AI)-powered, structure-based, drug design technology, which allows scientists to predict how well a small molecule will bind to a target protein of interest. By removing sole reliance on empirical screening, AI enables drug researchers to test an extremely large and diverse chemical space in a matter of days and move through the optimization process q
Jan 07, 2019 08:00 am ET
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 8th, at 10:00 a.m. PST (1:00 p.m. EST), followed by a question and answer session at 10:30 a.m. PST (1:30 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.
Dec 07, 2018 08:00 am ET
Investor Expectations to Drive Momentum within Raytheon, S&P Global, Teledyne Technologies, Nordstrom, Charles River Laboratories International, and U.S. Silica — Discovering Underlying Factors of Inf
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Raytheon Company (NYSE:RTN), S&P Global Inc. (NYSE:SPGI), Teledyne...
Nov 27, 2018 04:46 pm ET
Charles River Laboratories to Present at Evercore ISI Investor Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore ISI HealthConX Conference in Boston on Thursday, November 29th, at 11:00 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments.
Nov 13, 2018 08:00 am ET
Charles River Laboratories Continues Commitment to Oncology Drug Discovery
Charles River Laboratories International, Inc. (NYSE: CRL) today announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for
Nov 07, 2018 07:00 am ET
Charles River Laboratories Announces Third-Quarter 2018 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2018. For the quarter, revenue was $585.3 million, an increase of 26.1% from $464.2 million in the third quarter of 2017. Revenue growth was driven by all three business segments, particularly the Discovery and Safety Assessment segment.
Oct 30, 2018 08:00 am ET
Charles River to Present Collaborative Methods at Neuroscience 2018
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together more than 30,000 researchers from 80 countries, will take place from November 3-7, in San Diego, California.
Oct 29, 2018 08:25 am ET
Market Trends Toward New Normal in Polaris Industries, NIKE, Charles River Laboratories International, Actuant, Caesarstone, and Enzo Biochem — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Polaris Industries Inc. (NYSE:PII), NIKE, Inc. (NYSE:NKE), Charles...
Oct 25, 2018 08:00 am ET
Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms.
Oct 16, 2018 08:00 am ET
Charles River Laboratories Awarded Five-Year, $95.7 Million Contract by the National Institute of Allergy and Infectious Diseases
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it was awarded a five-year, $95.7 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), which is one of the largest institutes of the National Institutes of Health (NIH). Under NIAID’s Division of Intramural Research animal care program, Charles River will manage and provide staffing for NIAID’s on-site vivarium and related research model operations. The program is required to ensure the humane care and use of research models, and the
Oct 10, 2018 04:30 pm ET
Charles River Laboratories Schedules Third-Quarter 2018 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2018 financial results on Wednesday, November 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 7th, at 8:30 a.m. ET.
Aug 30, 2018 04:37 pm ET
Charles River Laboratories to Present at September Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including:
Aug 08, 2018 07:00 am ET
Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2018. For the quarter, revenue from continuing operations was $585.3 million, an increase of 24.8% from $469.1 million in the second quarter of 2017. Revenue growth was driven by all three business segments, particularly the Discovery and Safety Assessment segment.
Aug 01, 2018 07:45 am ET
Research Report Identifies Myriad Genetics, Celldex Therapeutics, Charles River Laboratories International, Louisiana-Pacific, Integrated Device Technology, and Beazer Homes with Renewed Outlook — Fun
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Myriad Genetics, Inc. (NASDAQ:MYGN), Celldex Therapeutics, Inc....
Jul 11, 2018 04:33 pm ET
Charles River Laboratories Schedules Second-Quarter 2018 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2018 financial results on Wednesday, August 8th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 8th, at 8:30 a.m. ET.
Jun 04, 2018 04:30 pm ET
Charles River Laboratories to Present at Jefferies and William Blair Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Jefferies 2018 Global Healthcare Conference in New York, New York, on Wednesday, June 6th, at 11:00 a.m. ET, and at the William Blair 38th Annual Growth Stock Conference in Chicago, Illinois, on Wednesday, June 13th, at 10:00 a.m. CT (11:00 a.m. ET). Management will present an overview of Charles River’s strategic focus and business developments.
May 29, 2018 01:49 pm ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Charles River Laboratories International, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, May 29, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Charles River Laboratories International, Inc. (NYSE: CRL). ...
May 10, 2018 07:00 am ET
Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2018. For the quarter, revenue from continuing operations was $494.0 million, an increase of 10.8% from $445.8 million in the first quarter of 2017. Revenue growth was driven primarily by the Discovery and Safety Assessment and Manufacturing Support segments.
May 03, 2018 08:00 am ET
Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation
Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). Since 2011, Charles River and MJFF have worked together t
May 01, 2018 08:00 am ET
Charles River Laboratories Expands Services for Early Discovery Screening
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its service capabilities in early discovery screening. Charles River is the first contract research organization to offer clients access to Apricot Designs' Dual Arm (ADDA) system for high-throughput absorption, distribution, metabolism, and excretion (HT-ADME) to identify potential lead compounds in North America and Europe. Additionally, the Company has geographically expanded its pharmacokinetic (PK) capabilities at sites central to major pharma
Apr 20, 2018 08:00 am ET
New Research Coverage Highlights MPLX LP, TESARO, LKQ, Cytokinetics, Keysight Technologies, and Charles River Laboratories International — Consolidated Revenues, Company Growth, and Expectations for 2
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MPLX LP (NYSE:MPLX), TESARO, Inc. (NASDAQ:TSRO),...
Apr 12, 2018 04:30 pm ET
Charles River Laboratories Schedules First-Quarter 2018 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2018 financial results on Thursday, May 10th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 10th, at 8:30 a.m. ET.
Apr 10, 2018 08:00 am ET
Charles River Laboratories Focuses on the Future of Oncology at AACR Annual Meeting 2018
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of oncology experts is presenting 13 scientific posters, both independently and collaboratively with clients, and will highlight an enhanced oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting. The meeting is taking place from April 14-18, 2018, at McCormick Place in Chicago, Illinois.
Apr 09, 2018 08:00 am ET
Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership
Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest today announced an expansion of their strategic partnership agreement to provide next-generation sequencing (NGS) services to the biologics industry. As part of the expanded partnership, Charles River intends to make a direct investment in PathoQuest.
Apr 03, 2018 08:30 am ET
Charles River Laboratories Announces Closing of Senior Notes Offering
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 5.5% senior notes due 2026 (the “notes”) in an unregistered offering. Charles River is issuing the notes as a strategic complement to its long-term capital structure.
Apr 03, 2018 08:30 am ET
Charles River Laboratories Completes the Acquisition of MPI Research
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of MPI Research for approximately $800 million in cash, subject to certain customary adjustments.
Mar 26, 2018 08:00 am ET
Charles River Laboratories Announces Refinancing of Credit Facilities and Offering of $500 Million of Senior Notes
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has refinanced its existing $1.0 billion of revolving credit facility due 2021 with a new $1.55 billion revolving credit facility due 2023, and its existing $650.0 million of term loan facility due 2021 with a new $750.0 million term loan facility due 2023 (the “credit facilities”). In addition, Charles River also announced today that, subject to market conditions, it intends to offer $500 million in aggregate principal amount of senior notes due 2026 (the “notes”
Mar 08, 2018 08:00 am ET
Charles River Laboratories Makes Expansions to Global Biologics Infrastructure
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced several key expansions to its global Biologics Testing Solutions infrastructure to support the characterization, development, and release of biologics and biosimilars. Growth in this industry has led to increased demand for outsourced services, providing an opportunity for Charles River to enhance capacity and capabilities in support of client needs.
Mar 05, 2018 08:00 am ET
Charles River Laboratories to Present at Raymond James and Barclays Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Florida, on Tuesday, March 6th, at 3:25 p.m. ET, and at the Barclays Global Healthcare Conference in Miami, Florida, on Wednesday, March 14th, at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus and business developments.
Feb 21, 2018 08:00 am ET
Charles River Laboratories Announces New Tumor Model Compendium
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced the launch of its new online Tumor Model Compendium web interface. The new Compendium interface provides oncology researchers with an easily accessible, user-friendly resource to identify tumor models based on specific molecul
Feb 16, 2018 07:40 am ET
Market Trends Toward New Normal in Tile Shop Holdings, Cytokinetics, Limelight Networks, CatchMark Timber Trust, Global Payments, and Charles River Laboratories International — Emerging Consolidated E
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tile Shop Holdings, Inc. (NASDAQ:TTS), Cytokinetics,...
Feb 13, 2018 07:02 am ET
Charles River Laboratories Announces Executive Management Appointments
Charles River Laboratories International, Inc. (NYSE: CRL) today announced two new executive management appointments.
Feb 13, 2018 07:01 am ET
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2017 Results from Continuing Operations and Provides 2018 Guidance
Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth-quarter and full-year 2017 and provided guidance for 2018. For the quarter, revenue from continuing operations was $478.5 million, an increase of 2.5% from $466.8 million in the fourth quarter of 2016. Revenue growth was driven by the Discovery and Safety Assessment and Manufacturing Support segments.
Feb 13, 2018 07:00 am ET
Charles River Laboratories to Acquire MPI Research
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, subject to customary closing adjustments.
Feb 01, 2018 08:00 am ET
Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
Jan 25, 2018 04:30 pm ET
Charles River Laboratories Schedules Fourth-Quarter 2017 Earnings and 2018 Guidance Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2017 financial results and provide 2018 guidance on Tuesday, February 13th, before the market opens. A conference call has been scheduled to discuss this information on Tuesday, February 13th, at 8:30 a.m. ET.
Jan 16, 2018 08:00 am ET
Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Jean-Paul Mangeolle, former President of AB SCIEX, to its Board of Directors. Mr. Mangeolle’s extensi
Jan 11, 2018 07:00 am ET
Charles River Laboratories Acquires KWS BioTest
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.
Jan 08, 2018 08:00 am ET
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9th, at 11:30 a.m. PST (2:30 p.m. EST), followed by a question and answer session at 12:00 p.m. PST (3:00 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.
Dec 06, 2017 08:00 am ET
Charles River Adds ERS License to CRISPR/Cas9 Service Offering
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CRISPR/Cas9 service offering with the addition of a license from ERS Genomics Limited. The license, coupled with the existing license through the
Dec 01, 2017 08:00 am ET
Investor Expectations to Drive Momentum within CatchMark Timber Trust, Global Payments, Charles River Laboratories International, Tile Shop Hldgs, Cytokinetics, and Limelight Networks — Discovering Un
NEW YORK, Dec. 01, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CatchMark Timber Trust, Inc. (NYSE:CTT),...
Nov 28, 2017 08:00 am ET
Charles River Announces Success of Integrated Discovery Project with ENYO Pharma
Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration. Together, the companies identified the mode of action of ENYO Pharma’s lead preclinical chemical series, EYP002, using Charles River’s newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology.
Nov 09, 2017 07:00 am ET
Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2017. Revenue from continuing operations was $464.2 million, an increase of 9.0% from $425.7 million in the third quarter of 2016. Revenue growth was driven primarily by the Discovery and Safety Assessment and Manufacturing Support segments.
Nov 01, 2017 08:00 am ET
Charles River Laboratories Presents Newly Expanded Capabilities at Neuroscience 2017
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts is presenting 27 scientific posters, both independently and collaboratively with clients, at Neuroscience 2017, the 47th annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together over 30,000 researchers from more than 80 countries, is taking place from November 11-15 in Washington, DC.
Oct 26, 2017 08:00 am ET
Charles River Announces Expansion of In Vitro Oncology Services
Charles River Laboratories International, Inc. (NYSE: CRL) today announced its partnership with InSphero AG, a leading supplier of 3D solutions for in vitro drug discovery and development.
Oct 12, 2017 04:30 pm ET
Charles River Laboratories Changes the Date of Its Third-Quarter 2017 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) has changed the date of its third-quarter 2017 earnings release and conference call. The Company will now release financial results on Thursday, November 9th, before the market opens. The conference call to discuss this information will be held on Thursday, November 9th, at 8:30 a.m. ET.
Oct 11, 2017 04:30 pm ET
Charles River Laboratories Schedules Third-Quarter 2017 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2017 financial results on Wednesday, November 8th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 8th, at 8:30 a.m. ET.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.